Incretin Effect in Patients With Psoriasis and Controls

Completed

• Conditions: Psoriasis Vulgaris
• Interventions: Diagnostic Test: Oral glucose tolerance test; Other: Intravenous isoglycaemic glucose clamp; Other: Liquid Mixed meal test

• Registration Number: NCT06064084
• Lead Sponsor: University Hospital, Gentofte, Copenhagen

Brief Summary

To investigate the incretin effect and postprandial incretin responses in plasma in patients with psoriasis

Detailed Description

Not available

Study Timeline

• Study Start: 2011-09-11
• Primary Completion: 2015-09-11
• Study Completion: 2015-09-11
• Status Verified: 2023-09
• Study First Submitted: 2023-09-14
• Study First Submitted QC: 2023-09-28
• Last Update Submitted: 2023-09-28
• Study First Posted: 2023-10-03
• Last Update Posted: 2023-10-03

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

no diabetes BMI < 27 kg/m^2 normal Glucose tolerance test at screening normal fasting plasma glucose no islet auto antibodies no hormonel contraception informed consent psoriasis vulgaris (PASI>8) (case not controls)

Exclusion Criteria

other chronic inflammtory skin disease other chronic inflammatory disease pregnancy psychiatric illness

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Psoriasis	Oral glucose tolerance test	-
Control	Oral glucose tolerance test	Age, Sex and BMI matched
Control	Liquid Mixed meal test	Age, Sex and BMI matched
Control	Intravenous isoglycaemic glucose clamp	Age, Sex and BMI matched
Psoriasis	Intravenous isoglycaemic glucose clamp	-
Psoriasis	Liquid Mixed meal test	-

Primary Outcome Measures

Name	Time	Method
Incretin effect measured with Beta-cell secretory response	0-180 minutes	Incretineffect (%) = 100 % × (Beta-cell Secretory Response (OGTT) - Beta-cell Secretory Response (IIGI)) / Beta-cell Secretory Response (OGTT)

Secondary Outcome Measures

Name	Time	Method
Concentration of Insulin	0-180 minutes	Evaluated as Area Under the Curve
Concentration of Glucagon-like peptide 1	0-180 minuntes	Evaluated as Area Under the Curve
Concentration of Glucagon	0-180 minutes	Evaluated as Area Under the Curve
Insulin sensitivity measures	0-180 minutes	Matsudas insulin sensitivity index: (10,000 / √glucose minute 0 x insulin minute 0) (mean glucose (OGTT) x mean insulin OGTT))
Concentration of Glucose-independent insulinotropic polypeptide	0-180 minutes	Evaluted as Area Under the Curve